FENC - Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc Logo

FENC - Fennec Pharmaceuticals Inc

https://fennecpharma.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in Research Triangle Park, North Carolina.

52W High
$9.42
52W Low
$3.96
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.59
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
15.77
EV/EBITDA (<8 favorable)
20.27
EV/Revenue (<3 favorable)
7.52
P/S (TTM) (<3 favorable)
7.52
P/B (<3 favorable)
57.93
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
16.12%
Institutions (25–75% balanced)
57.88%
Shares Outstanding
27,831,700
Float
14,564,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
33,302,000
Gross Profit (TTM)
29,936,000
EPS (TTM)
-0.45
Profit Margin (>10% good)
-0.36%
Operating Margin (TTM) (higher better)
-0.28%
ROE (TTM) (>15% strong)
-10.06%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.33
Momentum
Bearish momentum
Value
0.1692
Previous
0.2071
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025